Trends in Biochemical Sciences
Volume 43, Issue 7, July 2018, Pages 481-483
LetterKRAS Activating Signaling Triggers Arteriovenous Malformations
Section snippets
Acknowledgments
This work was supported by K99HL138272 from NHLBI. This work has been funded in whole or in part with Federal funds from the Frederick National Laboratory for Cancer Research, National Institutes of Health, under contract HHSN261200800001E to R.N.
References (10)
Calmodulin and PI3K signaling in KRAS cancers
Trends Cancer
(2017)- et al.
Pulmonary comorbidity in lung cancer
Trends Mol. Med.
(2018) Brain arteriovenous malformations
Nat. Rev. Dis. Primers
(2015)Structural causes of ischemic and hemorrhagic stroke in children: moyamoya and arteriovenous malformations
Curr. Opin. Pediatr.
(2015)Somatic activating KRAS mutations in arteriovenous malformations of the brain
N. Engl. J. Med.
(2018)
There are more references available in the full text version of this article.
Cited by (12)
A human model of arteriovenous malformation (AVM)-on-a-chip reproduces key disease hallmarks and enables drug testing in perfused human vessel networks
2022, BiomaterialsCitation Excerpt :The inability of a MEKi to reduce vessel size in AVM-on-a-chip vessels suggests that other cell types or signaling pathways may be affected by KRAS activation in ECs [44]. KRAS is one of the most frequently mutated oncogenes in cancer and plays a central role in several growth factor receptor tyrosine kinase signaling pathways [7,8,59,60]. As a result, targeting the MAPK/ERK and KRAS protein activity for cancer treatment is of high interest.
Nitric oxide synthase and reduced arterial tone contribute to arteriovenous malformation
2023, Science AdvancesMicroenvironment changes in arteriovenous malformations after stereotactic radiation
2022, Frontiers in Human NeuroscienceRecent advances in the study of somatic mutations in vascular malformations
2020, Chinese Journal of Plastic Surgery
© 2018 Elsevier Ltd. All rights reserved.